Search | Clinical Trials Finder

Conditions: Astrocytoma, Glioma, Oligodendroglioma
Interventions: Hepatitis A Vaccine, Laboratory Biomarker Analysis, Tetanus Toxoid Vaccine, Trivalent Influenza Vaccine; Biological · Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Hepatitis A
Interventions: hepatitis A vaccine; Biological
Lead sponsor: Centers for Disease Control and Prevention; Federal
Eligibility: 6 Months to 25 Years
Enrollment: 248 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1996 – 2001
U.S. locations: 2
States / cities: Anchorage, Alaska

Conditions: Rheumatic Diseases
Interventions: Hepatitis A vaccine, Diphtheria, pertussis, and tetanus booster vaccine; Biological
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years and older
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 7
States / cities: Northport, Alabama • Riverview, Florida • Boise, Idaho + 4 more

Conditions: Meningitis, Meningococcal
Interventions: rLP2086 vaccine, control; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 10 Years to 25 Years
Enrollment: 5,715 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 39
States / cities: Huntsville, Alabama • Chandler, Arizona • Tempe, Arizona + 28 more

Conditions: Infections, Papillomavirus
Interventions: Cervarix™, Havrix™-based investigational formulation; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 15 Years to 25 Years · Female only
Enrollment: 18,729 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2009
U.S. locations: 50
States / cities: Birmingham, Alabama • Fountain Valley, California • San Diego, California + 39 more

Conditions: Infections, Meningococcal
Interventions: Bexsero, Saline Placebo, Havrix, MenABCWY; Biological · Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 10 Years to 18 Years
Enrollment: 1,063 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 13
States / cities: Jonesboro, Arkansas • Hialeah, Florida • Melbourne, Florida + 10 more

Conditions: Varicella, Rubella, Mumps, Measles
Interventions: Priorix-Tetra™ (MMRV vaccine 208136), ProQuad®, Havrix®, Prevnar®; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Months to 14 Months
Enrollment: 1,851 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 141
States / cities: Birmingham, Alabama • Tuscaloosa, Alabama • Phoenix, Arizona + 125 more

Conditions: Chickenpox
Interventions: Investigational varicella vaccine low potency, Investigational varicella vaccine medium potency, Investigational varicella vaccine high potency, Licensed varicella vaccine Lot 1, Licensed varicella vaccine Lot 2, Measles, mumps, and rubella vaccine, Hepatitis A vaccine, 13-valent pneumococcal conjugate vaccine; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Months to 15 Months
Enrollment: 800 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 41
States / cities: Bryant, Arkansas • Jonesboro, Arkansas • Little Rock, Arkansas + 37 more

Conditions: Infections, Papillomavirus
Interventions: Gynaecological follow-up; Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 2,022 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 18
States / cities: Clearwater, Florida • Miami, Florida • Honolulu, Hawaii + 14 more

Conditions: Measles, Mumps, Rubella, Measles-Mumps-Rubella Vaccine
Interventions: Priorix, M-M-R II, Varivax, Havrix, Prevnar 13; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Months to 15 Months
Enrollment: 4,538 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2015
U.S. locations: 40
States / cities: Birmingham, Alabama • Phoenix, Arizona • Jonesboro, Arkansas + 33 more

Conditions: Pneumococcal Immunization
Interventions: PCV21 vaccine, Prevnar 20 vaccine, M-M-R II vaccine, Rotarix, RotaTeq, Vaxelis vaccine, Varivax, Priorix, VAQTA, Havrix; Biological
Lead sponsor: Sanofi; Industry
Eligibility: 42 Days to 89 Days
Enrollment: 580 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 17
States / cities: Los Angeles, California • Hollywood, Florida • Miami, Florida + 13 more

Conditions: Transplant-Related Cancer
Interventions: Havrix, PCV13; Biological
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Hepatitis A
Interventions: Havrix®, M-M-R®II, VARIVAX®; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Months to 13 Months
Enrollment: 1,474 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2009
U.S. locations: 42
States / cities: Cabot, Arkansas • Jonesboro, Arkansas • North Little Rock, Arkansas + 37 more

Conditions: Healthy Participants
Interventions: Vitamin A supplementation, No vitamin A supplementation; Biological
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 1 Year to 4 Years
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Healthy Volunteers (Meningococcal Infection)
Interventions: MenACYW conjugate vaccine, MenACYW-135 conjugate vaccine, DTaP-IPV//Hib vaccine, Pneumococcal 13-valent conjugate vaccine, Pentavalent rotavirus vaccine, Hepatitis B vaccine, Measles, mumps, rubella (MMR) vaccine, Varicella vaccine, Hepatitis A vaccine; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 42 Days to 89 Days
Enrollment: 2,627 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2023
U.S. locations: 65
States / cities: Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 54 more

Conditions: Herpes Simplex
Interventions: GSK208141, Havrix (investigational formulation), Placebo; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 10 Years to 17 Years · Female only
Enrollment: 5,960 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2007
U.S. locations: 66
States / cities: Birmingham, Alabama • Chandler, Arizona • Mesa, Arizona + 54 more

Conditions: Hepatitis A
Interventions: GSK Biologicals 2-dose inactivated hepatitis A vaccine (Havrix), Prevnar™; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Months to 13 Months
Enrollment: 521 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2006
U.S. locations: 18
States / cities: Centennial, Colorado • Bardstown, Kentucky • Louisville, Kentucky + 13 more

Conditions: Meningococcal Vaccine
Interventions: rLP2086, Havrix (HAV), Saline; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 10 Years to 18 Years
Enrollment: 3,596 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 62
States / cities: Birmingham, Alabama • Dothan, Alabama • Harrisburg, Arkansas + 42 more

Conditions: Hepatitis A
Interventions: Havrix™, Infanrix™, ActHIB™; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Months to 13 Months
Enrollment: 468 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2007
U.S. locations: 22
States / cities: Phoenix, Arizona • Oakland, California • San Ramon, California + 18 more

Conditions: Rubella, Mumps, Measles, Measles-Mumps-Rubella Vaccine
Interventions: GSK Biological's investigational vaccine 209762, M-M-R® II (Merck and Co), Varivax®, Havrix®, Prevnar®; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Months to 15 Months
Enrollment: 1,259 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2012
U.S. locations: 45
States / cities: Tuscaloosa, Alabama • Conway, Arkansas • Jonesboro, Arkansas + 42 more

Conditions: Herpes Simplex Infection
Interventions: HSV vaccine or SB208141, GSK Biologicals' glycoprotein D (gD)-Alum/3-deacylated form of Monophosphoryl Lipid A (MPL) candidate genital herpes vaccine, Havrix™, GlaxoSmithKline (GSK) Biologicals' licensed Hepatitis A vaccine; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 30 Years · Female only
Enrollment: 8,323 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2009
U.S. locations: 67
States / cities: Birmingham, Alabama • Chandler, Arizona • Mesa, Arizona + 56 more

Conditions: Measles; Mumps; Rubella, Measles-Mumps-Rubella Vaccine
Interventions: Priorix, M-M-R II, Varivax, Havrix, Prevnar 13; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Months to 15 Months
Enrollment: 1,742 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 80
States / cities: Birmingham, Alabama • Tucson, Arizona • Fayetteville, Arkansas + 69 more

Conditions: Pneumococcal Immunization
Interventions: PCV21 vaccine, Prevnar 20 vaccine, M-M-R II vaccine, Rotarix, RotaTeq, Vaxelis vaccine, Varivax, Priorix, VAQTA, Havrix; Biological
Lead sponsor: Sanofi; Industry
Eligibility: 42 Days to 89 Days
Enrollment: 2,360 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 103
States / cities: Birmingham, Alabama • Guntersville, Alabama • Oneonta, Alabama + 81 more

Conditions: Meningitis, Meningococcal
Interventions: Meningococcal ACWY Conjugate Vaccine, DTaP-IPV-HBV, Hib, Rotavirus, Pneumococcal 7-valent Conjugate Vaccine, HAV, MMR-V, DTaP; Biological
Lead sponsor: Novartis Vaccines; Industry
Eligibility: 2 Months to 2 Months
Enrollment: 4,545 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 53
States / cities: Bessemer, Alabama • Birmingham, Alabama • Downey, California + 43 more

Search by objective public record fields.

Qualitative, Qualitative, and Functional Studies Over the First Year in Measuring Immune System Response During the First Year of Therapy in Patients With Brain Tumors

Immunogenicity Study of an Inactivated Hepatitis A Vaccine in Infants and Young Children

The COVID-19 VaccinE Response and Co-Administration in Rheumatology Patients (COVER-CoAd)

A Global Phase 3 Safety Study of 120 mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years

Human Papilloma Virus (HPV) Vaccine Efficacy Trial Against Cervical Pre-cancer in Young Adults With GlaxoSmithKline (GSK) Biologicals HPV-16/18

Trial to Assess Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Meningococcal ABCWY Vaccine as Compared to Meningococcal B Vaccine in Adolescents

Immunogenicity and Safety of GlaxoSmithKline Biologicals' MMRV Vaccine vs. ProQuad® in Children 12-14 Months of Age

A Study on the Immune Response and Safety of Various Potencies of an Investigational Chickenpox Vaccine Compared With a Marketed Chickenpox Vaccine, Given to Healthy Children 12 to 15 Months of Age

Gynaecological Follow-up of a Subset of 580299/008 (NCT00122681) Study Subjects

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life

Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age

Patient-donor Vaccination in the Context of Allogeneic Bone Marrow Transplant With Post-transplant Cyclophosphamide

Immunogenicity & Safety of Hepatitis A Vaccine Co-admin With a Measles/Mumps/Rubella & a Varicella Vaccine in Children

Trial of Antibody Responses by Vitamin Supplementation

Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US

Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old

Immune Response & Safety of a Hepatitis A Vaccine Given Together With a Pneumococcal Vaccine in Healthy Children 15 m of Age

A Trial to Assess the Lot Consistency, Safety, Tolerability and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Subjects Aged ≥10 to <19 Years

Immunogenicity and Safety of Havrix™ Co-Administered With a Diphtheria, Tetanus and Pertussis and a Haemophilus b Vaccine in Children Aged 15 Months

Immunogenicity of GSKs' MMR Vaccine (209762) vs. M-M-R® II, When Given With Routine Vaccines at 12-15 Months of Age

HerpeVac Trial for Young Women

Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck & Co., Inc.'s MMR Vaccine in Healthy Children 12 to 15 Months of Age

Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age

A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Infants